DIFFUSE LARGE B CELL LYMPHOMA

This early-stage study aimed to find the safest dose of a new four-drug combination (romidepsin plus GDP) for patients with two types of aggressive lymphoma that had returned after prior treatment. The main goal was to determine how much of the new drug could be added without cau…

This early-stage study tested a new type of CAR-T cell therapy called C-CAR066 in a small group of patients with an aggressive form of lymphoma (DLBCL) whose cancer had come back after they had already received a different CAR-T treatment. The main goals were to check if the trea…

This early-phase study tested the safety of a modified chemotherapy regimen, called dose-adjusted EPOCH-R, in children with aggressive B-cell cancers like diffuse large B-cell lymphoma. The treatment involved giving some drugs as a continuous infusion over four days and adjusting…

This early-phase study tested the safety and best dose of a new drug called BGB-10188. It was given alone or combined with other cancer drugs to 97 patients with advanced blood cancers or solid tumors that had returned or stopped responding to prior treatments. The main goal was …

This small study tested a new, more convenient way to give radiation therapy to people with hard-to-treat B-cell lymphoma before they received CAR T-cell therapy. Instead of daily treatments, participants received radiation once a week for five weeks. Researchers wanted to see if…

This study tested whether adding a targeted drug called polatuzumab vedotin to a standard chemotherapy combination (R-GemOx) could help people with an aggressive type of lymphoma that had come back or stopped responding to prior treatments. It involved 270 adults whose cancer had…

This early-stage study tested the safety and highest tolerable dose of a new, genetically modified immune cell therapy called PRGN-3007 UltraCAR-T in adults with advanced blood cancers and triple-negative breast cancer. The main goal was to see how much of the treatment patients …

This trial tested two different drug combinations for patients with an aggressive type of blood cancer called DLBCL, who could not receive the standard chemotherapy due to heart risks or older age. It directly compared adding a newer targeted drug (inotuzumab ozogamicin) to a sta…

This study tested whether a drug called chidamide could help prevent cancer from coming back in patients who have both a type of lymphoma and hepatitis B. It involved 30 adults whose lymphoma had completely disappeared after initial chemotherapy. The goal was to see if taking chi…

This study tested whether adding the immunotherapy drug pembrolizumab after a patient's own stem cell transplant could help keep certain aggressive lymphomas from returning. It involved 82 adults with Hodgkin lymphoma, diffuse large B-cell lymphoma, or T-cell lymphoma that had co…

This first-in-human study tested a new oral drug called BR101801 in adults with advanced blood cancers that had returned or stopped responding to other treatments. The main goals were to find a safe dose and see how the body processes the drug. Researchers also looked for early s…

This study tested a new type of personalized immune therapy called BZ019 (a CAR-T cell therapy) in adults with aggressive B-cell lymphomas that had returned or stopped responding to standard treatments. The main goals were to find a safe dose and see if the therapy could shrink t…

This study tested whether adding the drug lenalidomide to standard R-CHOP chemotherapy works better for people with medium-to-high risk diffuse large B-cell lymphoma. Researchers followed 60 previously untreated patients to see if this combination could keep the cancer from retur…

This study aimed to understand how a specific cancer treatment called axi-cel (a type of CAR-T cell therapy) affects patients' thinking, memory, mood, and daily life. Researchers followed 60 adults with certain types of lymphoma who were scheduled to receive this commercial thera…

This study aims to create a detailed map of immune and cancer cells in patients with diffuse large B-cell lymphoma. Researchers will follow 60 patients receiving standard R-CHOP treatment for two years, analyzing blood and tumor samples to identify biomarkers that could predict t…

This study aimed to understand how a person's genetic makeup affects how quickly their body processes a high-dose chemotherapy drug called methotrexate, which is used to treat certain lymphomas. Researchers studied 20 adult patients to see if specific gene variations were linked …

This study aimed to understand when to best measure cancer DNA in the blood after lymphoma patients start chemotherapy. Researchers tracked 24 adults with diffuse large B-cell lymphoma right after their first treatment. The goal was to see if measuring DNA at a specific time coul…